OBJECTIVE: To probe into the clinical efficacy of losartan combined with oral iron preparation in the treatment of elderly chronic kidney disease（ CKD） complicated with anemia

and analyze its effect on hemoglobin（ Hb） level. METHODS: Totally 120 elderly patients with CKD admitted into the Eighth People’s Hospital of Hebei during Jan. 2019 to Jan. 2021 were selected and divided into control group and combined group via random dual-color ball. Based on the recombinant human erythropoietin for subcutaneous injection

60 patients in control group was treated with oral iron preparation

while the 60 patients in combined group was given losartan combined with oral iron preparation. The clinical efficacy

indicators of anemia [Hb

hematocrit value（ Hct） and red blood cell count（ RBC） ]

indicators of iron metabolism [transferrin（ TRF）

ferritin（ Fer）

serum Fe and total iron binding capacity（ TIBC） ]and micro-inflammation [high-sensitivity C-reactive protein（ hs-CRP）

interleukin 6（ IL-6）

interleukin 8（ IL-8） and nuclear factor κB（ NF-κB） ] at before and after treatment were compared between two groups. The incidence of adverse drug reactions were observed. RESULTS: The total effective rate of combined group was 95. 00%（ 57/60）

which was significantly higher than that of the control group（ 73. 33%

44/60）

with statistically significant difference（ P<0. 05）. Compared with before treatment

the Hb

RBC and Hct levels of both groups at 1 month

3 months and 6 months after treatment had been significantly increased

the intra-group difference before and after treatment was statistically significant（ P < 0. 05）. The Hb

RBC and Hct levels of combined group at 3 months and 6 months after treatment were significantly higher than those of the control group

with statistically significant differences in comparison between two groups（ P<0. 05）. After 6 months of treatment

the TRF

Fe and TIBC levels of both groups had been significantly increased

and those of combined group were significantly higher than the control group; the Fer levels of both groups had been significantly decreased

and that of combined group was significantly lower than the control group

with statistically significant differences（ P < 0. 05）. After 6 months of treatment

the CRP

IL-6

IL-8 and NF-κB levels of both groups had been significantly decreased

and those of combined group were significantly lower than the control group

with statistically significant differences（ P<0. 05）. The incidence of adverse drug reactions of combined group was 3. 33%（ 2/60）

which was significantly lower than that of the control group（ 16. 67%

10/60）

with statistically significant differences（ P<0. 05）. CONCLUSIONS: The combination of losartan and oral iron preparation is helpful to improve the efficacy of elderly CKD

promote anemia indicators including Hb

improve amenia situation

iron metabolism and micro-inflammation

reduce adverse drug reactions.